Eloralintide

peptide · endocrine · digestive · Subcutaneous

Eloralintide, a peptide. Long-acting, selective amylin receptor agonist investigated in clinical trials for obesity.

Long-acting, selective amylin receptor agonist investigated in clinical trials for obesity.

PK: Full text PMID:41109426 section 3.2.3 reports terminal geometric mean half-lives of 310–366 h and median Tmax of 72.0–132.2 h across dose cohorts. Paired Table S11 values are needed before fitting a single absorption/elimination model; a default absorption rate would incorrectly move the peak into the first day. DOSE: PMID:41207310 studied weekly SC 1, 3, 6, and 9 mg and 6–9 or 3–9 mg escalation regimens over 48 weeks. These are investigational trial arms, not an established dose.

Sources: PMID:41559929, PMID:41207310, PMID:41109426